Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.


Gordon, SB; Malamba, R; Mthunthama, N; Jarman, ER; Jambo, K; Jere, K; Zijlstra, EE; Molyneux, ME; Dennis, J; French, N; (2008) Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine, 26 (42). pp. 5400-5406. ISSN 0264-410X DOI: 10.1016/j.vaccine.2008.07.082

[img]
Preview
Text - Published Version
License:

Download (665Kb) | Preview

Abstract

We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) on pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and 1 month after injected (n=16) or inhaled (n=17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type 1 IgA in both serum and BAL (type 1 geometric mean BAL IgG 9.8ng/ml post-vaccine vs. 5ng/ml pre-vaccine, p=0.01; type 9V geo mean 5.6ng/ml vs. 2.7ng/ml, p=0.001; type 14 geo mean 23.6ng/ml vs. 6.2ng/ml, p=0.02). Inhaled vaccine produced no response in either BAL or serum.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Vaccine Centre
PubMed ID: 18708114
Web of Science ID: 259936600012
URI: http://researchonline.lshtm.ac.uk/id/eprint/6946

Statistics


Download activity - last 12 months
Downloads since deposit
222Downloads
296Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item